While therapies capable of mental and physical improvements can see both direct and indirect benefits, measurement standards are necessary to adequately assess those benefits, the National Pharmaceutical Council suggests in a new study.
NPC surveyed U.S. providers, pharmacy benefit managers, employee benefit consultancies, and employer group representatives to evaluate their opinions on the feasibility of evaluating indirect benefits.
“While all respondents rated traditional outcome measures such as efficacy, safety and cost as highly important in value assessments, survey results showed that the inclusion of indirect benefits was of low importance to payers, but of higher importance to employer stakeholders,” NPC said in a blog post.
To read the full blog post, click here.
To read the study in the Journal of Occupational and Environmental Medicine, click here.